AN advisory panel of the US Food and Drug Administration ( FDA ) yesterday recommended marketing approval for the drug Taxol to treat ovarian cancer which does not respond to standard treatment , writes Karen Zagor in New York . Bristol-Myers Squibb , the manufacturer , said it submitted its new drug application about two and a half years ahead of schedule . The FDA usually follows the panel 's recommendations . Analysts have predicted sales of Taxol , derived from the bark of rare Pacific yew trees , of up to Dollars 50m ( Pounds 33.1m ) next year , growing to about Dollars 350m by 1995 .